Contemporary considerations for neoadjuvant chemotherapy in primary ovarian cancer |
| |
Authors: | Peter E Schwartz |
| |
Institution: | 1. Department of Obstetrics, Gynecology and Reproductive Sciences, 33 Cedar Street, New Haven, CT, 06520, USA
|
| |
Abstract: | Surgery is essential for the successful treatment of patients with advanced ovarian cancer. Recent reports have raised questions
about the best time to perform surgery with regard to administering chemotherapy. A prospective randomized clinical trial
comparing neoadjuvant chemotherapy (ie, platinum-based chemotherapy before attempting cytoreductive surgery) and conventional
treatment (ie, aggressive cytoreductive surgery followed by platinum-based chemotherapy) demonstrated no difference in progression-free
and overall survival between the two treatment groups. The trial demonstrated the need for optimum surgical cytoreduction
regardless of whether surgery is performed before or after neoadjuvant chemotherapy. As the postoperative morbidity and mortality
was lower in the neoadjuvant treatment group, neoadjuvant chemotherapy should be considered a standard treatment for women
with advanced ovarian cancer, particularly those unlikely to be surgically cytoreduced to no residual tumor. This article
reviews contemporary considerations in the use of neoadjuvant chemotherapy in the treatment of primary ovarian cancer. |
| |
Keywords: | |
本文献已被 SpringerLink 等数据库收录! |
|